Abstract: Percutaneous transluminal renal artery stenting (PTRAS) has been proved to have no more benefit than medication alone in treating atherosclerotic renal artery stenosis (ARAS). Whether PTRAS could improve left ventricular hypertrophy (LVH) and reduce adverse events when based on percutaneous coronary intervention (PCI) for patients with coronary artery disease (CAD) and ARAS is still unclear. A retrospective study was conducted, which explored the effect of concomitant PCI and PTRAS versus PCI alone for patients with CAD and ARAS complicated by heart failure with preserved ejection fraction (HFpEF). A total of 228 patients meeting inclusion criteria were divided into two groups: (1) the HFpEF-I group, with PCI and PTRAS; (2) the HFpEF-II group, with PCI alone. Both groups had a two-year follow-up. The left ventricular mass index (LVMI) and other clinical characteristics were compared between groups. During the follow-up period, a substantial decrease in systolic blood pressure (SBP) was observed in the HFpEF-I group, but not in the HFpEF-II group. There was marked decrease in LVMI in both groups, but the HFpEF-I group showed a greater decrease than the HFpEF-II group. Regression analysis demonstrated that PTRAS was significantly associated with LVMI reduction and fewer adverse events after adjusting for other factors. In HFpEF patients with both CAD and ARAS, concomitant PCI and PTRAS can improve LVH and decrease the incidence of adverse events more than PCI alone. This study highlights the beneficial effect of ARAS revascularization, as a new and more aggressive revascularization strategy for such high-risk patients.
Introduction
Atherosclerotic renal artery stenosis (ARAS) and coronary artery disease (CAD) are independently associated with major cardiovascular events and confer a high risk of death in patients with CAD (Park et al., 2004; Kane et al., 2010) . Previous studies have shown that about 40% of patients with renovascular stenosis are complicated with cardiac diastolic dysfunction, such as heart failure with preserved ejection fraction (HFpEF) (Little and Brucks, 2005; Wright et al., 2005; Asrar ul Haq et al., 2014) . The progression of HFpEF reportedly is accelerated by myocardial ischemia (Middleton et al., 2001; Ronco and di Lullo, 2014) . Revascularization of coronary arteries for CAD or renal arteries for ARAS can relieve left ventricular hypertrophy (LVH), which is considered a strong indicator for death and cardiovascular complications. LVH has been the ideal surrogate for HFpEF assessment. Although previous studies supported a neutral recommendation for percutaneous transluminal renal artery stenting (PTRAS) versus medication in the general RAS population, there is little evidence as to whether concomitant percutaneous coronary intervention (PCI) and PTRAS, compared with PCI and medication alone, can better improve LVH in patients with both CAD and ARAS. As renal vascular intervention was not mentioned in guidelines for treatment of heart failure (McMurray et al., 2012) , the purpose of the present study is to evaluate the effect of concomitant PCI and PTRAS versus that of PCI and medication alone for patients with both CAD and ARAS complicated by HFpEF, and to determine whether PTRAS could improve the long-term prognosis of these high-risk patients.
Materials and methods

Subjects
Patients with CAD and ARAS who had undergone concomitant PCI and/or PTRAS were retrospectively enrolled. ARAS was defined as a ≥50% luminal stenosis of a renoartery confirmed by catheter selective renoarterial angiography. Coronary angiography was carried out using the Judkins technique. CAD was defined as coronary artery lesions graded as a >40% narrowing of the luminal diameter in the left main coronary artery (LMCA) or >70% in the left anterior descending artery (LAD), left circumflex coronary artery (LCX), right coronary artery (RCA), or the main branches. Significant stenosis in any vessel of the LAD, LCX, or RCA was defined as single, double, or triple vessel disease. Stenosis in the LMCA was considered equal to double vessel disease. The indications of renoarterial angiography included: a history of severe hypertension before 30 or after 55 years of age; progressive deterioration of renal function after angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) initiation; flush pulmonary edema; unexplained angina or heart failure; refractory and severe hypertension, and coexisted with multiple coronary disease. HFpEF was defined as a left ventricular ejection fraction (LVEF) of >50% and N-terminal pro-brain natriuretic peptide (NT pro-BNP) of >220 pg/ml, as well as the typical symptoms (e.g. breathlessness, orthopnoea, paroxysmal nocturnal dyspnea, reduced exercise tolerance, ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, hepatojugular reflux, gallop rhythm, pulmonary crackles, and displaced apex beat) (McMurray et al., 2012) . Normal cardiac function was defined as an LVEF of >50% and NT pro-BNP of <220 pg/ml. Patients were divided into two groups according to interventional procedures: (1) the HFpEF-I group, undergoing concomitant PCI and PTRAS; and (2) the HFpEF-II group, undergoing PCI alone. Baseline characteristics of the patients including blood pressure (BP), cardiac and renal function, and serum lipid profile were compared with those measured after the two-year follow-up, within and between groups ( Table 1) . The exclusion criteria were as follows: patients with CAD or ARAS only, or patients with acute myocardial infarction (AMI), chronic renal failure with routine hemodialysis, functioning kidney with a serum creatinine (SCr) of >4 mg/dl, size of targeted kidney <8 cm, coronary or renal artery lesion anatomy not suitable for stenting, renal artery stenosis secondary to fibromuscular dysplasia (FMD), or vasculitis.
Data collection
Eligible patients were prescribed antiplatelet drugs (aspirin plus plavix or ticlopidine), statin, ACEI or ARB, and β-blockers, calcium channel blocker, nitrates or diuretics. BP was measured three times consecutively at resting status during an interval of at least 5 min (Chobanian et al., 2003) . Left ventricular systolic function was assessed by LVEF using modified Simpson's method (Folland et al., 1979) . The left ventricular mass index (LVMI) was used for evaluating cardiac diastolic function by normalizing left ventricular mass (LVM) over the body surface area (BSA) (Levy et al., 1990) . The formulas used were as follows: LVM=1.04× ((LVEDd+IVSd+LVPWd) 3 − LVEDd 3 )−13.6, where LVEDd is left ventricular end diastolic dimension, IVSd is interventncular septal thickness at diastole, and LVPWd is left ventricular posterior wall at diastole; LVMI=LVM/BSA.
The estimated glomerular filtration rate (eGFR, ml/min per 1.73 m 2 ) was estimated by the CockroftGault formula incorporating age (A), sex, body weight (BW), and SCr concentration (c SCr , mg/dl) as follows: eGFR=((140-A)×BW)/(c SCr ×72)×(0.85, if women). An eGFR of <60 ml/min per 1.73 m 2 was defined as moderate to severe renal dysfunction (Patel et al., 2002) . Diagnostic criteria for contrast-induced nephropathy (CIN) were as follows: an SCr increase of 44.2 µmol/L or 25% of baseline value and an SCr of ≥110 µmol/L within 48 h of undergoing iodinated contrast injection. Major adverse clinical events (MACEs) included all-cause mortality, AMI, unstable angina pectoris, congestive heart failure, resuscitation from cardiac arrest, and stroke.
Intervention
PTRA and PCI were performed using standard techniques by a femoral or radial artery approach. Heparin was infused to achieve an activated clotting time of at least 200 s during stent implantation. Coronary and renal artery stenosis was measured as the percentage of the decrease in luminal diameter. Coronary stenting was performed for significant narrowing lesions (>40% narrowing of the LMCA and >70% narrowing of other branches). Renoarterial stenting was performed if there was a ≥50% organic stenosis of the luminal diameter or a systolic pressure gradient of at least 20 mmHg across the stenotic lesion. Pre-or post-dilation of the target lesions was carried out if necessary. Technical success was defined as a <20% residual stenosis of the luminal diameter.
Statistical analysis
Statistical analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Continuous variables with a normal distribution are expressed as mean±standard deviation (SD). Means were compared by independent Student's t-tests. Categorical variables are presented as percentages and were analyzed by χ 2 test. The significance level of this study was set at two-tailed α=0.05. Multivariate logistic regression and linear analysis were used to estimate MACEs and LVMI variation during the two-year follow-up.
Results
Patients and baseline characteristics
A total of 1112 patients with concomitant coronary and renoarterial selective angiography between January 2003 and December 2011 in our hospital were screened; 228 patients with both ARAS and CAD were enrolled in the study, and 805 patients with only CAD and 32 patients with only ARAS were excluded. Thirty-one patients with AMI and 16 patients with FMD were also excluded. The percentages of single-, double-, and triple-vessel coronary artery lesions in the study population were 18.9%, 30.7%, and 50.4%, respectively (Table 1 ). The baseline LVMI value and systolic blood pressure (SBP) level were significantly higher in the HFpEF-I group than in the HFpEF-II group. The indications for undergoing PTRAS procedures included refractory hypertension (53.8%, 84/156), progressive renal dysfunction (16.0%, 25/156), flash pulmonary edema (7.1%, 11/156), and silent but severe renal artery stenosis (23.1%, 36/156). There were no significant differences in age, sex, history of hypertension and diabetes mellitus, the distribution of ARAS type, angiographic severity of coronary lesions, LVEF, or renal function between the HFpEF-I and the HFpEF-II groups (Table 1) . The proportion of patients who received ACEI/ARB therapy was significantly lower in the HFpEF-II group than in the HFpEF-I group (Table 1) .
Relationship between stent numbers, contrast volume, and CIN prevalence
The average accumulated volume of contrast for simultaneous coronary and renal stenting was (172.7±49.4) ml, and the CIN occurrence rate was 18.4% among all patients. The contrast volume and CIN occurrence and the average number of coronary stents were not significantly different between the HFpEF-I and HFpEF-II groups (Table 2 ).
Clinical outcomes after interventional procedures
Patients were followed up for at least two years (the mean duration of follow-up was (28.7±16.0) months) after the revascularization procedures. Within groups, BP, eGFR, LVEF, and LVMI were compared before and two years after the revascularization procedures were performed. There was a significant decrease in SBP. A greater decrease in SBP was observed in the HFpEF-I group than in the HFpEF-II group (Δ= (21.60±5.24) mmHg vs. Δ=(7.49±3.13) mmHg, P< 0.001). The LVEF within and between groups did not change significantly in the post-intervention period (Fig. 1c) (Fig. 1d) . Linear analysis found that PTRAS and better BP control contributed significantly to LVMI improvement (Table 3) . In both groups, there was no significant change in eGFR from before undergoing the revascularization procedures until two years after treatment (P>0.05) (Fig. 1e) . 
MACEs
After the revascularization procedures, 7 patients died during hospitalization and 29 died during the two-year follow-up period. Perioperative deaths were attributed to: cardiac causes (n=5), sepsis shock (n=1), and cerebral hemorrhage (n=1). Deaths during the two-year follow-up were attributed to cardiac causes (n=14), renal failure and multiple organ dysfunction syndrome (n=4), pneumonia or other causes of respiratory failure (n=4), stroke (n=2), cancer (n=3), and cataclasis (n=2). There was no significant difference in death rate between the HFpEF-I and HFpEF-II groups during follow-up, but the rate of MACEs in the HFpEF-I group was significantly lower than that in the HFpEF-II group (31.4% vs. 48.6%, P=0.004; Table 4 ). The HFpEF-II group had a significantly higher incidence of unstable angina pectoris (7.7% vs. 18.1%, P<0.001) and congestive heart failure (7.1% vs. 11.1%, P=0.019) than the HFpEF-I group during follow-up. Multivariable logistic regression showed that PTRAS was significantly associated with fewer MACEs (P=0.031; Table 5 ). 
Discussion
Although prior trials indicated that PTRAS was no better than medication in the general renal artery stenting (RAS) population (Simon, 2010) , only one study considered CAD and RAS together, and that study lacked details of the coronary intervention (Marcantoni et al., 2012) . In our study, we found that PTRAS could further relieve LVH based on PCI, and reduce the incidence of MACEs. As ARAS has been recognized as a common and significant independent risk factor for survival in patients with cardiovascular disease (Hirsch et al., 2006) , our results indicate that revascularization for ARAS in addition to PCI, is a potentially beneficial treatment for such high-risk patients with CAD and ARAS.
It has been reported that about one third of patients with CAD have coexisting ARAS, with or without HFpEF (Przewlocki et al., 2008) . Mechanisms by which coexistence of CAD and ARAS is associated with HFpEF are under investigation (Groban and Kitzman, 2010; Wang and Shi, 2014) . The progressive increase in cardiac diastolic dysfunction leading to a worsening of CAD and ARAS is partly explained by factors such as increased afterload, renal hypertension resulting from ARAS, myocardial ischemia, overactivation of RAAS, and inflammation (Ding et al., 2014) . Risks that increase with coexisting CAD and ARAS complicated by HFpEF include oxidative stress, de-arrangements in calcium-phosphate homeostasis, and conditions promoting coagulation, all of which share similar pathogenic factors associated with accelerated atherosclerosis and endothelial dysfunction (de Silva et al., 2005; Liu et al., 2015) . The Angioplasty and Stent for Renal Artery Lesions (ASTRAL) trial and the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) studies showed no significant difference in the ability of PTRAS or medicine alone to lower BP and CV (Wheatley et al., 2009; Cooper et al., 2014) . The Renal Artery Stenosis in Coronary Artery Disease (RASCAD) study also drew a negative conclusion but lacked details of the coronary intervention, which may have affected the results from PTRAS (Marcantoni et al., 2012) . The intervention may have included controversial inclusion criteria or neglected the effects of coronary atherosclerosis or cardiorenal interaction. In the present study, we considered systemic atherosclerosis and the potential interaction between CAD and ARAS, and confirmed the diagnosis by selective artery angiography to exclude false positive or negative stenosis by echo or computed tomographic arteriography (CTA). Coronary stenosis was resolved to guarantee myocardium perfusion. In our study, significant differences in the extent of the reduction in SBP between the HFpEF-I and HFpEF-II groups reflected an effective role of PTRAS in controlling SBP for HFpEF patients. The results could further explain why concomitant PCI and PTRAS led to a greater reduction in the LVMI than PCI alone. This effect may be due to the blocking of the vicious circle of the renin-angiotensin-aldosterone system (RAAS) as well as the inhibition of vasoconstriction by angiotensin and water-sodium retention. As the regression of LVMI may have been influenced by BP control and RAAS inhibitors, we performed a linear analysis of ∆LVMI (difference between baseline and follow-up LVMI values) and found that the effect of PTRAS on LVMI improvement remained significant even after adjusting for the above factors. LVMI has usually been used as an ideal indicator of cardiovascular events. PTRAS was found to be associated with a reduction in the LVMI, suggesting that concomitant revascularization of coronary and renal arteries was associated with a greater improvement in cardiac diastolic function than coronary revascularization alone. Hypothetical mechanisms by which coronary and renal revascularization might have increased cardioprotection in our study may include a superior control of hypertension, better perfusion to the myocardium, and relief of RAAS overactivity. Improved coronary circulation could contribute to the balance between myocardial energy requirements and oxygen supply, and relief of myocardial stiffness. A previous cohort study had demonstrated that diastolic function was significantly and independently associated with BP response and follow-up survival in patients undergoing open renal revascularization (Ghanami et al., 2011) . The extent of systolic BP improvement in our study was more significant in the HFpEF-I group than in the HFpEF-II group. Moreover, the prescription rate of ACEI/ARB was also much higher in the HFpEF-I group than in the HFpEF-II group (81.4% vs. 68.1%). This was probably due to revascularization of RAS giving physicians much more confidence to prescribe RAAS inhibitors, which were the core drugs for RAS treatment.
Similar to previous studies (Dean et al., 1981) , we found insignificant changes in eGFR during the follow-up period whether or not PTRAS was performed. However, whether the patient received PTRAS or not, the CIN rate in our study was not significantly different between groups, and was comparable with the rates reported in other studies (Chábová et al., 2000; Su et al., 2013) . In our study, additional PTRAS was significantly associated with a lower incidence of overall MACEs. This may be explained by better control of BP, the decrease in the LVMI, and more prescription of ACEI/ARB. However, the comparison of HFpEF-I with HFpEF-II in death rate was negative, suggesting that PTRAS still could not improve the long-term survival of patients in this condition.
As a retrospective study, our study has inevitable limitations of sample size and matching of baseline data. A future intervention study will be needed to verify our findings. In conclusion, PTRAS could further relieve LVH based on PCI, and reduce MACEs to some extent. This highlights ARAS as a potential therapeutic target and provides evidence supporting a more aggressive strategy of RAS intervention in CAD and RAS with HFpEF, when PCI is performed.
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